PMID- 33907384
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 15
DP  - 2021
TI  - Patient Preferences for Subcutaneous versus Intravenous Administration of 
      Treatment for Chronic Immune System Disorders: A Systematic Review.
PG  - 811-834
LID - 10.2147/PPA.S303279 [doi]
AB  - BACKGROUND: For many chronic immune system disorders, the available treatments 
      provide several options for route of administration. The objective of this 
      systematic literature review is to inform discussions about therapy choices for 
      individual patients by summarizing the available evidence regarding the 
      preferences of patients with chronic immune system disorders for intravenous (IV) 
      or subcutaneous (SC) administration. METHODS: Searches of the MEDLINE, Embase and 
      Cochrane Library databases were conducted using terms designed to capture studies 
      reporting patient preferences between IV and SC therapy published in English. 
      Relevant studies were limited to those in which mode of administration, including 
      treatment frequency and setting, was the main difference between comparators. 
      RESULTS: In total, 49 studies were included in the review. Among 18 studies that 
      compared IV and SC immunoglobulin therapy, 16 found patients to prefer the SC 
      administration route. The results of the 31 studies comparing IV infusion and SC 
      injection of non-immunoglobulin therapies were mixed, with patients favoring SC 
      administration in 20, IV infusion in seven, and having no overall preference in 
      four. Patient experience had a strong effect on preferences, with 
      treatment-experienced patients preferring their current administration route in 
      most studies. Patients preferring SC administration tended also to prefer 
      treatment at home, mainly due to the convenience and comfort of home treatment 
      and the avoidance of having to attend hospital. By contrast, patients preferring 
      IV infusion tended to cite the lower treatment frequency and a dislike of 
      self-injecting, and preferred hospital treatment, mainly due to the presence of 
      healthcare professionals and resulting feelings of safety. CONCLUSION: In general 
      patients with chronic immune system disorders tend to be more likely to choose SC 
      administration than IV infusion, but preferences may vary according among 
      individuals. These findings may assist discussions around appropriate treatment 
      choices for each patient.
CI  - (c) 2021 Overton et al.
FAU - Overton, Paul M
AU  - Overton PM
AUID- ORCID: 0000-0002-1557-3413
AD  - Beacon Medical Communications, Brighton, UK.
FAU - Shalet, Natalie
AU  - Shalet N
AD  - NAS Healthcare Solutions, London, UK.
FAU - Somers, Fabian
AU  - Somers F
AD  - UCB Pharma, Brussels, Belgium.
FAU - Allen, Jeffrey A
AU  - Allen JA
AUID- ORCID: 0000-0001-8753-2680
AD  - Department of Neurology, Section of Neuromuscular Medicine, University of 
      Minnesota, Minneapolis, MN, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210419
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC8064718
OTO - NOTNLM
OT  - administration route
OT  - autoimmune disorders
OT  - decision making
OT  - immunodeficiency
OT  - preference
OT  - systematic literature review
COIS- Jeffrey Allen has acted as a consultant for Argenx, Akcea Therapeutics, CSL 
      Behring and Grifols. He has also received grants from CSL Behring, personal fees 
      from Grifols, and personal fees from Argenx, outside the submitted work. Paul 
      Overton is a director of Beacon Medical Communications Ltd, which received 
      funding for this project from UCB Pharma, and additional project funding from UCB 
      Pharma, outside the submitted work. He also received personal fees from Beacon 
      Medical Communications Ltd, during the conduct of the study. Natalie Shalet is a 
      director of NAS HealthCare solutions Ltd, which provided consultancy services to 
      UCB Pharma during this project. Fabian Somers is an employee of UCB Pharma. The 
      authors report no other conflicts of interest in this work.
EDAT- 2021/04/29 06:00
MHDA- 2021/04/29 06:01
PMCR- 2021/04/19
CRDT- 2021/04/28 06:18
PHST- 2021/01/22 00:00 [received]
PHST- 2021/03/19 00:00 [accepted]
PHST- 2021/04/28 06:18 [entrez]
PHST- 2021/04/29 06:00 [pubmed]
PHST- 2021/04/29 06:01 [medline]
PHST- 2021/04/19 00:00 [pmc-release]
AID - 303279 [pii]
AID - 10.2147/PPA.S303279 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2021 Apr 19;15:811-834. doi: 10.2147/PPA.S303279. 
      eCollection 2021.